SEARCH:   Advanced

Blood, 30 April 2009, Vol. 113, No. 18, pp. 4144-4152. Prepublished online as a Blood First Edition Paper on January 23, 2009; DOI 10.1182/blood-2008-10-184200. This Article Full Text (PDF) All Versions of this Article: blood-2008-10-184200v1 113/18/4144    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tam, C. S Articles by Khouri, I. F Search for Related Content PubMed PubMed Citation Articles by Tam, C. S Articles by Khouri, I. F Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 16, 2008 Accepted January 7, 2009 Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Constantine S Tam, Roland Bassett, Celina Ledesma, Martin Korbling, Amin Alousi, Chitra Hosing, Partow Kebraei, Robyn Harrell, Gabriela Rondon, Sergio A Giralt, Paolo Anderlini, Uday Popat, Barbara Pro, Barry Samuels, Frederick Hagemeister, L. Jeffrey Medeiros, Richard E Champlin, and Issa F Khouri* Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Medical Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States * Corresponding author; email: ikhouri{at}mdanderson.org. In this study, we analyzed the long-term outcome of a risk-adapted transplantation strategy for mantle cell lymphoma in 121 patients enrolled in sequential transplantation protocols at the UT MD Anderson Cancer Center. Notable developments over the 17-year study period were the addition of rituximab to chemotherapy and preparative regimens and the advent of non-myeloablative allogeneic stem cell transplantation (NST). In the autologous transplantation group (n=86), rituximab resulted in a marked improvement in progression-free survival for patients transplanted in their first remission (where a plateau emerged at 3 - 8 years), but did not change the outcomes for patients transplanted beyond their first remission. In the NST group, composed entirely of patients transplanted beyond their first remission, durable remissions also emerged in progression-free survival at 5 - 9 years. The major determinants of disease control after NST were the use of a peripheral blood stem cell graft and donor chimerism of 95%, while the major determinant of transplant-related death was immunosuppression for chronic graft-vs-host disease. Our results demonstrate that long-term disease free survival in mantle cell lymphoma is possible after rituximab-containing autologous transplantation for patients in first remission, and after NST for patients with relapsed or refractory disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020